



0960-894X(95)00127-1

DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY  
RELATIONSHIPS OF  
2-SUBSTITUTED-2-AMINO-1,3-PROPANEDIOLS: DISCOVERY OF  
A NOVEL IMMUNOSUPPRESSANT, FTY720.

Kunitomo Adachi\*, Toshiyuki Kohara, Noriyoshi Nakao, Masafumi Arita, Kenji Chiba,  
Tadashi Mishina, Shigeo Sasaki<sup>a</sup>, and Tetsuro Fujita\*<sup>b</sup>

Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., 7-25 Koyata 3-chome,  
Iruma-shi, Saitama 358, Japan


<sup>a</sup> Research Laboratory, Taito Co., Ltd., 1-26 Higashi Shiriike-shinmachi, Nagata-ku, Kobe 653,  
Japan

<sup>b</sup> Faculty of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-01, Japan

**Abstract:** FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), a novel synthetic immunosuppressant led by modification of ISP-I (myriocin, thermozyomicidin) displayed potent immunosuppressive activity both *in vitro* and *in vivo*.

As reported in the preceding communication<sup>1</sup>, simplification of the structure of ISP-I including removal of the side chain functionalities as well as elimination of chiral centers led to 2-alkyl-2-amino-1,3-propanediols such as **1a-c** (Figure 1). Some of them displayed more potent immunosuppressive activity than ciclosporin, which is currently used clinically. In addition to that, the toxicity of ISP-I was reduced to a considerable extent although it was still insufficient. Here, we displaced a part of the alkyl chain of **1a-c** with sterically equivalent 1,4-phenylene group in expectation of modifying their physicochemical, pharmacological, toxicological, or pharmacokinetic property. In this communication, we describe the design, synthesis, and structure-activity relationships of thus modified compounds.


Figure 1




**Design:** Each of 2-amino-1,3-propanediols (**1a-c**) consists of both a hydrophilic part (amino alcohol) and a lipophilic part (hydrocarbon chain). The amphiphilicity should be one of the most important features of these compounds. The lipophilic side chain contains a number of rotatable bonds. The activity would be improved if conformation of the compound can be properly restricted. We planned to introduce a phenyl ring, which was considered an effective template for restricting the conformation of molecules<sup>2</sup>, into the lipophilic side chain of **1** maintaining the total amphiphilicity of the molecule. We chose **1a** as a lead compound because **1a** had proved less toxic than **1b**<sup>3</sup>. We prepared a series of compounds possessing a phenyl ring on a variety of positions within the side chain keeping the chain length constant ( $m+n=10$ ) (Figure 1).

**Synthesis:** Compounds **2b-h**<sup>4</sup> were synthesized by a similar route to that described in the preceding paper<sup>1</sup> but (4-alkylphenyl)alkyl halides (**3b-h**: X=Br or I) were used instead of the simple alkyl bromides (Scheme 1). Compound **2a** was prepared in a totally different way (Scheme 2). 4-Decylbenzyl bromide (**4**) was nitrated with silver nitrate to give nitro compound, which was bishydroxymethylated using formalin and sodium hydroxide in ethanol<sup>5</sup> followed by reduction with Raney-nickel to afford the desired compound **2a**.

**Scheme 1. Synthesis of 2b-h.**



**Scheme 2. Synthesis of 2a.**



**Results and discussion:** Compounds **2a-h** were evaluated for their ability to inhibit mouse allogeneic MLR ( $IC_{50}$ ) *in vitro* (Table 1)<sup>6</sup>.


**Table 1. Effect of 2a-h on mouse allogeneic MLR**

	2a	2b	2c	2d	2e	2f	2g	2h
$IC_{50}$ (nM)	13	70	6.1	350	19	100	32	54

All the compounds displayed moderate to potent inhibitory activity. Compound **2c** (FTY720) was most potent among them and demonstrated comparable activity to the lead compound **1a**<sup>7</sup> ( $IC_{50}$  = 5.9nM). Moving the phenyl ring of **2c** toward each direction by only one carbon (compounds **2b** and **2d**) resulted in a great loss in potency, suggesting that it is of critical importance for the potent activity where the phenyl ring is positioned within the side chain. Some "even-odd effect" was observed concerning the compounds **2a-2e**. The compounds **2a**, **2c**, and **2e**, the number of whose methylene units between the aminopropanediol terminus and the phenyl ring is even, were much more potent than the others (**2b** and **2d**: odd number).

Compounds **1a** and **2c** were evaluated in rat skin allograft in combination with LEW donor and F344 recipient *in vivo* (Figure 2)<sup>8</sup>. FTY720 (**2c**) displayed remarkable immunosuppressive activity *in vivo* and prolonged rat skin allograft survival in a dose dependent manner. It was approximately 3-fold more potent than **1a**.

**Figure 2. Effect of 1a and 2c on rat skin allograft**



Compound **2c** also displayed excellent immunosuppressive activity in other administration routes *in vivo* (mean survival time: 24.8days/0.1mg/kg, 46.3days/3mg/kg, and 53.5days/10mg/kg, *iv*; 19.3days/0.1mg/kg, 41.0days/3mg/kg and 57.8days/30mg/kg, *po*). Moreover, **2c** was not toxic in the rat skin allograft up to a dose of 10mg/kg, *iv*, while compounds **1a** and **1b** were toxic<sup>9</sup> at a dose of 10 and 3mg/kg, *iv*, respectively. Our preliminary data show that the mechanism

of action of **2c** is different from that of ciclosporin and FK506<sup>10,11</sup>. Although **2c** did not inhibit the production of interleukin-2 unlike ciclosporin and FK506, it inhibited immune responses by selective depletion of mature T-cells probably caused by lymphocyte migration and apoptosis (data not shown here<sup>12</sup>).

**Conclusion:** We incorporated a phenyl ring into the side chain of the lead compound **1a** to obtain a novel immunosuppressant, FTY720 (**2c**), which displayed remarkable immunosuppressive activity both *in vitro* and *in vivo* as well as significant improvement in side effects. FTY720 (**2c**) is expected as a powerful candidate for safer immunosuppressant<sup>13</sup> for organ transplantations and for the treatment of autoimmune diseases.

#### References and Notes:

1. Fujita, T.; Yoneta, M.; Hirose, R.; Sasaki, S.; Inoue, K.; Kiuchi, M.; Hirase, S.; Adachi, K.; Arita, M.; Chiba, K. *BioMed. Chem. Lett.*, preceding communication of this issue.
2. Moore, G.J. *TIPS*. **1994**, *15*, 124.
3. When intraperitoneally administered in the rat skin allograft, **1b** displayed intenser local irritation than **1a**.
4. All new compounds in this communication gave satisfactory analytical and spectroscopic data in full accord with their assigned structures.
5. Feuer, H.; Nielsen, A. T.; Colwell, C. E. *Tetrahedron* **1963**, *19*, Suppl. 1, 57.
6. The effect of the compounds on mouse allogeneic MLR was examined by the method described in our previous paper: Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T. *J. Antibiotics* **1994**, *47*, 208.
7. We also prepared 2-amino-2-[2-(4-nonylphenyl)ethyl]-1,3-propanediol (IC<sub>50</sub>=8.5nM) corresponding to **1b**. It exhibited a slight decrease in potency compared with **1b** (IC<sub>50</sub>=2.9 nM).
8. The effect of the compounds on rat skin allograft was examined by the method described in the preceding paper<sup>1</sup>.
9. The term "toxic" used here means that animals die at indicated doses.
10. Mechanism of action : (a) Schreiber, S. L. *Science* **1991**, *251*, 283. (b) Liu, J.; Farmer, Jr., J. D.; Lane, W. S.; Friedman, J.; Weissmann, I.; Schreiber, S.L. *Cell* **1991**, *66*, 807. (c) Schreiber, S. L. *Cell* **1992**, *70*, 365.
11. FK506 : (a) Tanaka, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Kino, T.; Goto, T.; Hashimoto, M.; Taga, T. *J. Am. Chem. Soc.* **1987**, *109*, 5031. (b) Kino, T.; Hatanaka, H.; Hashimoto, M.; Nishiyama, M.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H.; Imanaka, H. *J. Antibiotics* **1987**, *40*, 1249.
12. Our study on mechanism of action of FTY720 (**2c**) will be reported in due course.
13. Ciclosporin and FK506 possess several adverse effects such as nephrotoxicity and neurotoxicity: (a) The U.S. Multicenter FK506 liver study group, *The New England Journal of Medicine* **1994**, *331*, 1110. (b) Japanese FK506 Study Group, *Transplantation Proceedings* **1993**, *25*, 649. (c) Japanese FK506 Study Group, *Transplantation Proceedings* **1991**, *23*, 3071.

(Received in Japan 20 February 1995; accepted 6 March 1995)